Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Barter

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
The American Journal of Cardiology|November 6, 2013
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart diseaseAntonio M Gotto, Christopher P Cannon, Xiujiang Susie Li, et al.
The New England Journal of Medicine|March 10, 2005
Intensive lipid lowering with atorvastatin in patients with stable coronary diseaseJohn C LaRosa, Scott M Grundy, David D Waters, et al.
Atherosclerosis|June 23, 2017
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURNRishi Puri, Christie M Ballantyne, Ron C Hoogeveen, et al.
Atherosclerosis|September 25, 2007
Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS StudyHeide Stirnadel, Xiwu Lin, Hua Ling, et al.
The New England Journal of Medicine|November 19, 2010
Safety of anacetrapib in patients with or at high risk for coronary heart diseaseChristopher P Cannon, Sukrut Shah, Hayes M Dansky, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|April 17, 2014
Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE studyAntonio M Gotto, Uma Kher, Manash Shankar Chatterjee, et al.
Circulation|October 30, 2007
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countriesBeverley Balkau, John E Deanfield, Jean-Pierre Després, et al.
Circulation. Cardiovascular Genetics|December 3, 2011
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studiesBenoit J Arsenault, S Matthijs Boekholdt, G Kees Hovingh, et al.
Plos One|December 23, 2014
Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
Journal of the American College of Cardiology|December 28, 2010
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
The American Journal of Cardiology|November 6, 2013
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart diseaseAntonio M Gotto, Christopher P Cannon, Xiujiang Susie Li, et al.
The New England Journal of Medicine|March 10, 2005
Intensive lipid lowering with atorvastatin in patients with stable coronary diseaseJohn C LaRosa, Scott M Grundy, David D Waters, et al.
Atherosclerosis|June 23, 2017
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURNRishi Puri, Christie M Ballantyne, Ron C Hoogeveen, et al.
Atherosclerosis|September 25, 2007
Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS StudyHeide Stirnadel, Xiwu Lin, Hua Ling, et al.
The New England Journal of Medicine|November 19, 2010
Safety of anacetrapib in patients with or at high risk for coronary heart diseaseChristopher P Cannon, Sukrut Shah, Hayes M Dansky, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|April 17, 2014
Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE studyAntonio M Gotto, Uma Kher, Manash Shankar Chatterjee, et al.
Circulation|October 30, 2007
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countriesBeverley Balkau, John E Deanfield, Jean-Pierre Després, et al.
Circulation. Cardiovascular Genetics|December 3, 2011
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studiesBenoit J Arsenault, S Matthijs Boekholdt, G Kees Hovingh, et al.
Plos One|December 23, 2014
Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
Journal of the American College of Cardiology|December 28, 2010
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
Pageof 8